CAT 3888

Drug Profile

CAT 3888

Alternative Names: BL 22; BL22 Immunotoxin - MedImmune LLC; GCR 3888; RFB4 (dsFv) PE38

Latest Information Update: 04 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge Antibody Technology; National Institutes of Health (USA)
  • Developer MedImmune
  • Class Antineoplastics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia; Lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 29 Oct 2007 Cambridge Antibody Technology has been integrated into MedImmune
  • 22 Jun 2006 Cambridge Antibody Technology has been acquired by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top